AstraZeneca PLC and its China-based partner Chi-Med (Hutchison China MediTech Ltd.) have highlighted preliminary clinical evidence that the addition of the investigational agent, savolitinib, to other anticancer therapies may be of clinical benefit in certain non-small cell lung cancer (NSCLC) patients whose tumors have become resistant to therapy.
Chi-Med's Savolitinib: Overcoming Treatment Resistance in NSCLC
China-based but UK- and US-quoted Chi-Med is building up clinical data for its late-stage anticancer savolitinib, this time in patients with treatment-refractory lung cancer.
More from Clinical Trials
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
More from R&D
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.